Published in Endocrinology on July 26, 2007
MicroRNAs regulate pituitary development, and microRNA 26b specifically targets lymphoid enhancer factor 1 (Lef-1), which modulates pituitary transcription factor 1 (Pit-1) expression. J Biol Chem (2010) 1.06
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res (2008) 0.98
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines. Cancer (2008) 0.93
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord (2010) 0.88
CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Mol Endocrinol (2011) 0.79
Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int J Mol Sci (2017) 0.75
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep (2017) 0.75
Contribution of molecular analysis to the typification of the non-functioning pituitary adenomas. PLoS One (2017) 0.75
Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab (2012) 2.87
Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab (2014) 2.01
Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem (2006) 2.00
Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes (2012) 1.91
Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev (2007) 1.79
Angiogenesis in endocrine tumors. Endocr Rev (2003) 1.50
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas. J Clin Invest (2011) 1.49
Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab (2008) 1.45
Pituitary hypoplasia in Pttg-/- mice is protective for Rb+/- pituitary tumorigenesis. Mol Endocrinol (2005) 1.40
Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metab (2011) 1.34
p21(Cip1) restrains pituitary tumor growth. Proc Natl Acad Sci U S A (2008) 1.31
Overexpressed pituitary tumor-transforming gene causes aneuploidy in live human cells. Endocrinology (2003) 1.29
Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology (2007) 1.25
Functional role of estrogen in pituitary tumor pathogenesis. J Clin Invest (2002) 1.24
Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology (2007) 1.23
Acromegaly. Endocrinol Metab Clin North Am (2008) 1.23
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab (2008) 1.19
Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) (2012) 1.19
Pituitary tumor transforming gene-null male mice exhibit impaired pancreatic beta cell proliferation and diabetes. Proc Natl Acad Sci U S A (2003) 1.19
PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest (2003) 1.18
Early multipotential pituitary focal hyperplasia in the alpha-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol Endocrinol (2005) 1.18
Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides (2009) 1.16
Body mass index determines evoked growth hormone (GH) responsiveness in normal healthy male subjects: diagnostic caveat for adult GH deficiency. J Clin Endocrinol Metab (2004) 1.15
Molecular targets in pituitary tumours. Nat Rev Cancer (2004) 1.14
The neuroprotective WldS gene regulates expression of PTTG1 and erythroid differentiation regulator 1-like gene in mice and human cells. Hum Mol Genet (2006) 1.14
Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med (2002) 1.14
Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res (2007) 1.09
Pituitary corticotroph ontogeny and regulation in transgenic zebrafish. Mol Endocrinol (2003) 1.09
Single-surgeon fully endoscopic endonasal transsphenoidal surgery: outcomes in three-hundred consecutive cases. Pituitary (2013) 1.08
The utility of oral glucose tolerance testing for diagnosis and assessment of treatment outcomes in 166 patients with acromegaly. J Clin Endocrinol Metab (2008) 1.08
Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest (2004) 1.06
Targeting zebrafish and murine pituitary corticotroph tumors with a cyclin-dependent kinase (CDK) inhibitor. Proc Natl Acad Sci U S A (2011) 1.05
Ectopic acromegaly due to growth hormone releasing hormone. Endocrine (2012) 1.05
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Minireview: Neuro-immuno-endocrine modulation of the hypothalamic-pituitary-adrenal (HPA) axis by gp130 signaling molecules. Endocrinology (2002) 1.04
Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology (2010) 1.04
Lipodystrophy in patients with acromegaly receiving pegvisomant. J Clin Endocrinol Metab (2008) 1.03
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
Pancreatic neuroendocrine tumors in glucagon receptor-deficient mice. PLoS One (2011) 1.02
Pituitary tumor transforming gene overexpression facilitates pituitary tumor development. Endocrinology (2006) 1.02
Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol (2004) 1.01
Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. Am J Physiol Endocrinol Metab (2008) 1.01
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands. Cancer Res (2008) 0.98
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab (2007) 0.97
Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab (2014) 0.96
Hypothalamic-pituitary cytokine network. Endocrinology (2003) 0.96
Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol (1985) (2007) 0.95
Lineage-specific restraint of pituitary gonadotroph cell adenoma growth. PLoS One (2011) 0.95
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab (2005) 0.95
Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle (2012) 0.95
Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity. Physiol Behav (2011) 0.94
A botulinum toxin-derived targeted secretion inhibitor downregulates the GH/IGF1 axis. J Clin Invest (2012) 0.94
Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int (2010) 0.93
Growth hormone is a cellular senescence target in pituitary and nonpituitary cells. Proc Natl Acad Sci U S A (2013) 0.93
Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol (2007) 0.92
No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol (2008) 0.92
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab (2010) 0.92
Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet (2011) 0.92
Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab (2006) 0.91
Acromegaly with moderate hyperprolactinemia caused by an intrasellar macroadenoma. Nat Clin Pract Endocrinol Metab (2006) 0.90
Ovarian hyperstimulation syndrome caused by an FSH-secreting pituitary adenoma. Nat Clin Pract Endocrinol Metab (2008) 0.90
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab (2003) 0.90
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy. Mol Endocrinol (2010) 0.90
Prolactin receptor signaling mediates the osmotic response of embryonic zebrafish lactotrophs. Mol Endocrinol (2005) 0.89
Aryl hydrocarbon receptor interacting protein variants in sporadic pituitary adenomas. J Clin Endocrinol Metab (2006) 0.89
Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab (2003) 0.89
A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology (2005) 0.89
Diminished pancreatic beta-cell mass in securin-null mice is caused by beta-cell apoptosis and senescence. Endocrinology (2009) 0.89
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab (2006) 0.89
Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes. Horm Cancer (2010) 0.88
Subclinical hyperfunctioning pituitary adenomas: the silent tumors. Best Pract Res Clin Endocrinol Metab (2012) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer (2008) 0.87
Heregulin regulates prolactinoma gene expression. Cancer Res (2009) 0.87
Changing patterns of the adult growth hormone deficiency diagnosis documented in a decade-long global surveillance database. J Clin Endocrinol Metab (2008) 0.87
Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol (2009) 0.86
Treatment of acromegaly: future. Endocrine (2005) 0.86
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. ChemMedChem (2010) 0.86
Prospective safety surveillance of GH-deficient adults: comparison of GH-treated vs untreated patients. J Clin Endocrinol Metab (2013) 0.86
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab (2005) 0.86
The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab (2004) 0.86
Functional association of somatostatin receptor subtypes 2 and 5 in inhibiting human growth hormone secretion. J Clin Endocrinol Metab (2003) 0.86
Ghrelin and its analogues, BIM-28131 and BIM-28125, improve body weight and regulate the expression of MuRF-1 and MAFbx in a rat heart failure model. PLoS One (2011) 0.85
Somatostatin receptors 1, 2, and 5 cooperate in the somatostatin inhibition of C6 glioma cell proliferation in vitro via a phosphotyrosine phosphatase-eta-dependent inhibition of extracellularly regulated kinase-1/2. Endocrinology (2008) 0.85
Selective regulation of somatostatin receptor subtype signaling: evidence for constitutive receptor activation. Mol Endocrinol (2007) 0.85